Annovis Bio, Inc.
NYSE:ANVSBiotechnology
+$0.00 today
- Market cap
- $51.64M
- Beta
- 1.24
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$1.47
Volume 1.35M
Average 1.08M
ANVS Total Current Liabilities
All obligations due within one year.
Annovis Bio, Inc.NYSE: ANVS
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities rises 410.7% from a year ago
Total current liabilities stood at $12.79M at the end of Q1 FY2026, up 410.7% from a year earlier and up 251.8% from the prior quarter. Over 3 fiscal years it compounded at -22.1% a year.
Context
- Total current liabilities amounted to 78.7% of total assets at the end of Q1 FY2026, up 69.4 pp from a year earlier.
- Total current liabilities increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +410.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 3.64M USD
- Year-over-year change
- -6.3%
- 4-year CAGR
- +24.6%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.64M | -6.3% |
| FY2024 | 2024-12-31 | 3.88M | -9.3% |
| FY2023 | 2023-12-31 | 4.28M | -44.4% |
| FY2022 | 2022-12-31 | 7.7M | +411.0% |
| FY2021 | 2021-12-31 | 1.51M | — |
Total Current Liabilities vs competitors
How ANVS compares with its peers on the latest reported figures
- ANVS's Mar 2026 total current liabilities of $12.79M is the 2nd highest of the 6 companies compared; the peer median is $9.26M.
- Its year-over-year change of +410.7% is the highest of 6, against a peer median of +11.4%.
- Total current liabilities amounts to 78.7% of total assets for ANVS, versus a peer median of 36.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | $80.76M | +50.4% | +9.2% | 75.2% | |
| Mar 2026 | $12.79M | +410.7% | -22.1% | 78.7% | |
| Mar 2026 | $10.15M | -44.4% | -1.2% | 41.1% | |
| Jun 2026 | $9.26M | +11.4% | -9.2% | 23.1% | |
| Mar 2026 | $7.05M | -43.1% | -3.3% | 36.8% | |
| Mar 2026 | $6.32M | +25.0% | +21.3% | 17.9% | |
| Peer median (excluding ANVS) | $9.26M | +11.4% | -1.2% | 36.8% | |
Competitors are the stored peer set for ANVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Annovis Bio, Inc.
NYSE:ANVS
Intrinsic Alpha fair value
Locked
Current Price
$1.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.